Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Deferred Revenue (2020 - 2025)

Maxcyte (MXCT) has disclosed Current Deferred Revenue for 6 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 31.48% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 31.48% year-over-year, with the annual reading at $3.6 million for FY2025, 31.48% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $3.6 million at Maxcyte, down from $5.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $7.3 million in Q2 2022, with the low at $2.6 million in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $5.4 million, with a median of $5.6 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue skyrocketed 39.31% in 2021, then tumbled 35.81% in 2023.
  • Over 5 years, Current Deferred Revenue stood at $6.7 million in 2021, then decreased by 0.5% to $6.7 million in 2022, then fell by 24.49% to $5.1 million in 2023, then rose by 3.59% to $5.3 million in 2024, then crashed by 31.48% to $3.6 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $3.6 million, $5.2 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.